Supporting this, bryostatin enhanced the activity of 2-Cda in a drug-resistant B-CLL cell line (WSU-CLL) by altering the Bcl-2/Bax expression ratio, increasing Bax and decreasing Bcl-2 [81]. This evidence concerns the gene BAX and B-cell chronic lymphocytic leukemia.